Trials / Recruiting
RecruitingNCT06212635
Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
Novel Biomarkers for Evaluation of Hemostasis and Inflammation in Liver Cirrhosis
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Region Stockholm · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
Detailed description
The rebalanced hemostasis in liver cirrhosis is vulnerable and patients are prone to both bleeding and thrombosis. There are today no gold standard for evaluating the hemostasis and we will evaluate novel methods for this.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | T-TAS | Blood test, laboratory assays |
Timeline
- Start date
- 2022-12-02
- Primary completion
- 2026-12-01
- Completion
- 2028-12-01
- First posted
- 2024-01-19
- Last updated
- 2024-01-19
Locations
1 site across 1 country: Sweden
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06212635. Inclusion in this directory is not an endorsement.